Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II HLA-mismatched unrelated allogeneic HCT with post-transplant cyclophosphamide
jRCTs051220057Phase 2Recruiting
- Start
- Jul 2022
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, tacrolimus and mycophenolate mofetil in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), acute leukemia of ambiguous lineage (ALAL) and 5 more. Primary endpoint: Grade III–IV acute GVHD-free survival at day 100. Started Jul 2022; status: recruiting.
02
Drugs
cyclophosphamidetacrolimusmycophenolate mofetil
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)acute leukemia of ambiguous lineage (ALAL)myelodysplastic syndrome (MDS)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on jRCTs051220057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220057.